Biolidics Ltd

Biolidics Limited is a company that develops and commercializes innovative diagnostic solutions, with a primary focus on oncology. The company's core product is the ClearCell FX1 System, a fully automated medical device that uses a novel patented technology to separate and enrich cancer cells from blood. The system is label-free, viable, and intact, allowing for the isolation of circulating tumor cells (CTCs) that can be used for various downstream applications, such as immunofluorescence, cytopathology, cytogenetics, and genetic analysis. The company aims to lower healthcare costs and improve clinical outcomes with its diagnostic solutions, and is also exploring technology-enabled lifestyle businesses to diversify its business model and drive long-term growth.

Incorporated in 2009 and listed on the Singapore Stock Exchange, Biolidics Limited (“Biolidics” or “the Company” and together with its subsidiaries “the Group”) is a precision medicine medical technology company with a focus in developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.

Our ClearCell® FX1 System is a fully automated device for cell retrieval that can separate and enrich wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood. It is driven by our CTChip®FR1 biochip, which is a single-use microfluidic biochip.

Covid 19 Kits